DGAP-News: Femprox(R) Phase III Clinical Data From Apricus Biosciences Chosen for a Presentation at the European Society for Sexual Medicine
Apricus Biosciences, Inc.
14.11.2011 15:47
—————————————————————————
SAN DIEGO, 2011-11-14 15:47 CET (GLOBE NEWSWIRE) —
Apricus Biosciences, Inc. (–Apricus Bio– or the –Company–) (Nasdaq:APRI)
announced today the acceptance of an abstract entitled, –Age Group Analysis of
a Randomized, Double-blind, Phase 3 study of Femprox(r), a Topical Alprostadil
Cream with a Novel Transdermal Delivery Technology (Nexact(r)) for the Treatment
of Female
